Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months)
In this retrospective cohort study, the real-world effectiveness of semaglutide 2.4 mg was demonstrated by reductions in weight and BMI along with improvements in BP, HbA1c, and lipid panel among patients with obesity or overweight.
Authors
- Samuel Huse (ORCID: https://orcid.org/0009-0001-7633-2293)
- Devika Umashanker (ORCID: https://orcid.org/0000-0002-5895-1015)
- Wojciech Michalak (ORCID: https://orcid.org/0000-0002-3390-0182)
- Nina Ding (ORCID: https://orcid.org/0009-0006-8950-3588)
- Anthony N. Fabricatore
- Aleksandrina Ruseva
- Beth Nordstrom (ORCID: https://orcid.org/0000-0003-1743-9610)
- Bríain ó Hartaigh
- Zhenxiang Zhao
- Firas Dabbous (ORCID: https://orcid.org/0000-0003-3713-3045)
Institutions
- Ithaka Harbors (US)
- Hartford Hospital (US)
- Novo Nordisk (United States) (US)
- Novo Nordisk (United Kingdom) (GB)
- UnitedHealth Group (United States) (US)
- Hartford Financial Services (United States)
Publication Details
- Journal
- Postgraduate Medicine
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1080/00325481.2025.2482274
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 10.36